Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M164,170Revenue $M24,890Net Margin (%)51.7Altman Z-Score7.8
Enterprise Value $M165,647EPS $7.4Operating Margin %64.0Piotroski F-Score8
P/E(ttm)12.7Beneish M-Score-2.3Pre-tax Margin (%)62.4Higher ROA y-yY
Price/Book9.610-y EBITDA Growth Rate %--Quick Ratio2.4Cash flow > EarningsY
Price/Sales6.65-y EBITDA Growth Rate %27.2Current Ratio2.7Lower Leverage y-yN
Price/Free Cash Flow11.0y-y EBITDA Growth Rate %180ROA % (ttm)44.1Higher Current Ratio y-yY
Dividend Yield %--PEG0.5ROE % (ttm)93.9Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M1,470ROIC % (ttm)84.4Gross Margin Increase y-yY

Gurus Latest Trades with GILD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GILDJulian Robertson 2015-03-31 Reduce-5.61%$94.91 - $107.18
($101.54)
$ 111.7110%Reduce 56.64%231,511
GILDLeon Cooperman 2015-03-31 Sold Out -0.96%$94.91 - $107.18
($101.54)
$ 111.7110%Sold Out0
GILDFirst Eagle Investment 2015-03-31 Reduce-0.3%$94.91 - $107.18
($101.54)
$ 111.7110%Reduce 99.97%400
GILDNWQ Managers 2015-03-31 Buy 0.14%$94.91 - $107.18
($101.54)
$ 111.7110%New holding113,100
GILDJohn Rogers 2015-03-31 Add0.1%$94.91 - $107.18
($101.54)
$ 111.7110%Add 11.07%891,645
GILDJoel Greenblatt 2015-03-31 Add0.07%$94.91 - $107.18
($101.54)
$ 111.7110%Add 9.73%1,107,732
GILDDavid Dreman 2015-03-31 Buy 0.05%$94.91 - $107.18
($101.54)
$ 111.7110%New holding5,580
GILDRonald Muhlenkamp 2015-03-31 Reduce$94.91 - $107.18
($101.54)
$ 111.7110%Reduce 0.09%218,740
GILDMario Gabelli 2015-03-31 Add$94.91 - $107.18
($101.54)
$ 111.7110%Add 16.13%49,470
GILDKen Fisher 2015-03-31 Add$94.91 - $107.18
($101.54)
$ 111.7110%Add 2.35%789,615
GILDDodge & Cox 2015-03-31 Reduce$94.91 - $107.18
($101.54)
$ 111.7110%Reduce 5.76%4,250
GILDKen Heebner 2014-12-31 Sold Out -4.7%$89.45 - $114.22
($103.4)
$ 111.718%Sold Out0
GILDJulian Robertson 2014-12-31 Add1.67%$89.45 - $114.22
($103.3)
$ 111.718%Add 20.27%533,911
GILDLeon Cooperman 2014-12-31 Buy 0.96%$89.45 - $114.22
($103.54)
$ 111.718%New holding612,500
GILDFirst Eagle Investment 2014-12-31 Add0.3%$89.45 - $114.22
($103.4)
$ 111.718%Add 328672.00%1,315,088
GILDJoel Greenblatt 2014-12-31 Add0.26%$89.45 - $114.22
($103.3)
$ 111.718%Add 51.98%1,009,462
GILDRonald Muhlenkamp 2014-12-31 Add0.24%$89.45 - $114.22
($103.4)
$ 111.718%Add 6.10%218,945
GILDJohn Rogers 2014-12-31 Add0.17%$89.45 - $114.22
($103.4)
$ 111.718%Add 24.68%802,803
GILDVanguard Health Care Fund 2014-12-31 Sold Out -0.1%$89.45 - $114.22
($103.4)
$ 111.718%Sold Out0
GILDMariko Gordon 2014-12-31 Sold Out -0.05%$89.45 - $114.22
($103.3)
$ 111.718%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GILD is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GILD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-05-15Sell70,000$109.452.06view
Alton Gregg HEVP, Corp & Med Affairs 2015-05-15Sell25,000$110.011.55view
Carter Paul RutherfordEVP Commercial Ops 2015-05-15Sell6,000$1101.55view
MILLIGAN JOHN FPresident and COO 2015-05-07Sell100,000$10110.6view
Carter Paul RutherfordEVP Commercial Ops 2015-05-01Sell2,000$103.188.27view
MARTIN JOHN CChairman and CEO 2015-05-01Sell150,000$104.956.44view
Alton Gregg HEVP, Corp & Med Affairs 2015-05-01Sell12,000$104.077.34view
Washington Robin LEVP, CFO 2015-05-01Sell16,842$105.066.33view
BISCHOFBERGER NORBERT WEVP, R&D and CSO 2015-04-15Sell70,000$103.847.58view
Alton Gregg HEVP, Corp & Med Affairs 2015-04-08Sell5,000$10011.71view

Press Releases about GILD :

    Quarterly/Annual Reports about GILD:

    News about GILD:

    Articles On GuruFocus.com
    Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
    Top-Ranked Analysts Are Bullish on Gilead Sciences, Inc. (GILD) May 14 2015 
    8 Top Healthcare Stocks to Watch May 13 2015 
    pharma May 10 2015 
    Julian Robertson's growing stocks trading at low P/E May 05 2015 
    Gilead Sciences Remains a Popular Biotech Stock Following Earnings May 03 2015 
    Looking Ahead of Wall Street: Apple, GoPro, Gilead Sciences Apr 27 2015 
    AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
    Weekly CFO Sells Highlight: Gilead Sciences Inc, CarMax Inc, Anthem Inc. Apr 20 2015 
    Current positions Apr 13 2015 

    More From Other Websites
    Large Companies With Fastest Revenue and Earnings Growth in 2015 May 24 2015
    Can Gilead keep growing without a big deal? May 23 2015
    The Most Loved Biotechs of Big Hedge Funds May 23 2015
    The best blue chips to own forever May 23 2015
    Will This Drug Beat Gilead to Market in NASH? May 22 2015
    Kite Pharma Starts Dosing in Phase I/II Study on KTE-C19 - Analyst Blog May 22 2015
    Gilead Sciences: Hep-C Prescriptions Continue to Fall May 22 2015
    Who are Gilead Sciences' (GILD) main competitors? May 22 2015
    What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors? May 21 2015
    Will the J&J Deal With Achillion Transform the Hep C Market? May 20 2015
    Top 10 stocks of the David Letterman era May 20 2015
    Achillion Dives As J&J Hep C Deal Chills Buyout Buzz May 20 2015
    Gilead Sciences Inc. (GILD), Yahoo! Inc. (YHOO) and Sinclair Broadcast Group Inc. (SBGI) Among the... May 20 2015
    Gilead patents on costly hepatitis C drug challenged in five countries May 20 2015
    Gilead patents on costly hepatitis C drug challenged in five countries May 20 2015
    Gilead patents on costly hepatitis C drug challenged in 5 countries May 20 2015
    Soaring Cash Makes Gilead Cheaper Than You Think May 20 2015
    UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19) May 20 2015
    High Price for Gilead Sciences Hep C Drug Prompts Patent Challenges May 20 2015
    Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J May 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK